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http://dx.doi.org/10.1016/j.trsl.2015Luteinized unruptured follicle (LUF) syndrome is one of the intractable ovulation
disorders that are commonly observed during cycles of treatment with ovulation
inducers, for which no effective therapy other than assisted reproductive technology
is available. Here, we investigated whether granulocyte colony-stimulating factor
(G-CSF) could prevent the onset of LUF syndrome. We analyzed the effects of
G-CSF in 68 infertile women with LUF syndrome who received ovulation induction
(clomiphene 1 human chorionic gonadotropin [hCG] therapy or follicle-
stimulating hormone1 hCG therapy). G-CSF (lenograstim, 100 mg) was administered
subcutaneously. Onsets of LUF syndrome were compared between the cycle during
which G-CSF was given in combination with the ovulation inducer (ie, the G-CSF
treatment cycle) and the subsequent cycle during which only the ovulation inducer
was given (ie, the G-CSF nontreatment control cycle). The results showed that LUF
syndrome recurred in only 3 cycles during the G-CSF treatment cycle (4.4% [3/68
cycles]), whereas LUF syndrome recurred in 13 cycles during the subsequent
G-CSF nontreatment control cycle (19.1% [13/68 cycles]). The additional use of
G-CSF significantly prevented the onset of LUF syndrome during ovulation induction
(P 5 0.013, McNemar test). No serious adverse reactions because of the administra-
tion of G-CSF were observed. In conclusion, our findings indicate that G-CSF may
become a useful therapy for LUF syndrome. (Translational Research 2016;171:63–70)Abbreviations: ART ¼ assisted reproductive technology; FSH ¼ follicle-stimulating hormone;
G-CSF ¼ granulocyte colony-stimulating factor; hCG ¼ human chorionic gonadotropin; LUF
¼ luteinized unruptured follicle; NSAIDs ¼ nonsteroidal anti-inflammatory drugs; WBC ¼ white
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.10.003INTRODUCTIONO vulation disorders are one of the majorcauses of female infertility.1 The selective es-trogen receptor modulator (clomiphene) or
gonadotropins (ie, follicle-stimulating hormone [FSH]
and human chorionic gonadotropin [hCG]) are widely
used for the treatment of ovulation disorders. Clomi-
phene is known to induce ovulation fairly well,2
whereas adverse effects of clomiphene lead to cervical
mucus insufficiency,3 thinning of the endometrium,4
and luteinized unruptured follicle (LUF) syndrome.563
AT A GLANCE COMMENTARY
Shibata T, et al.
Background
As a part of cancer chemotherapy, granulocyte
colony-stimulating factor (G-CSF) has been used
for at least 30 years in clinical practice for the treat-
ment of neutropenia. No serious adverse drug reac-
tions have been reported with the use of G-CSF, to
the best of our knowledge.
Translational Significance
The present study clinically demonstrated that
G-CSF is useful for infertile women diagnosed
with luteinized unruptured follicle caused by
ovulation induction.
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which the luteinization of ovarian follicles is observed
without follicle rupture or ovum extrusion.5 Although
the cause of LUF syndrome is still unknown, groups
have suggested that endometriosis6,7 or the use of
nonsteroidal anti-inflammatory drugs (NSAIDs) during
the periovulatory phase8 could cause LUF syndrome.
Because NSAIDs inhibit not only the production of
prostaglandin but also neutrophil chemotaxis,9,10
reduced inflammatory reactions because of NSAID
use during ovulation could contribute to the onset of
LUF syndrome.
A well-known hypothesis proposed by Espey11 in
1980 focused mainly on the mechanism of ovulation
as an inflammatory reaction. Neutrophils, which play
a central role in inflammatory reactions, infiltrate the
thecal layer during the periovulatory phase of the men-
strual cycle.12 Granulocyte colony-stimulating factor
(G-CSF) is generally known as a cytokine that induces
inflammatory reactions, thereby enhancing neutrophil
function, and G-CSF and its receptor are known to be
produced by granulosa cells.13 We reported that the
G-CSF messenger RNA levels in granulosa or theca
cells were increased by at least 10-fold during the pre-
ovulatory late follicular phase compared with other
phases of the menstrual cycle,14 suggesting an impor-
tant role for G-CSF in the mechanism of ovulation
during the late follicular phase.
In the field of cancer chemotherapy, recombinant
human G-CSF has been used for at least 30 years in clin-
ical practice for the treatment of neutropenia. No serious
adverse drug reactions have been linked to the use of
G-CSF, to the best of our knowledge. Under these cir-
cumstances, we conducted the present study to evaluatewhether the administration of an inducer of inflamma-
tory reaction, G-CSF, would be feasible as a treatment
for LUF syndrome.METHODS
Patients. Infertile women who had been diagnosed
with LUF syndrome at least once participated in the pre-
sent clinical study. The inclusion criteria were as
follows: age ,40 years and no severe pelvic adhesions
around the ovaries and fallopian tubes as assessed by
laparoscopy. The exclusion criteria were as follows:
(1) white blood cell (WBC) count $10,000/mL at the
time of the administration of G-CSF; (2) severe disor-
ders of the liver, kidney, or heart; (3) allergic predispo-
sition; and (4) any other conditions assessed by the
investigator as leading to the patient being ineligible
for participation in the study. To evaluate the effects
of the additional use of G-CSF on LUF syndrome, we
compared the number of cycles showing a recurrence
of LUF syndrome between the cycle during which
G-CSF was given in combination with ovulation in-
ducers (clomiphene 1 hCG therapy or FSH 1 hCG
therapy; ie, the G-CSF treatment cycle) and the subse-
quent cycle during which only prescribed therapy was
given (ie, the G-CSF nontreatment control cycle). The
type, dose, and duration of each ovulation inducer
were tightly equalized between the G-CSF treatment
cycle and the G-CSF nontreatment control cycle.
The present study was conducted at the Department
of Obstetrics and Gynecology of Kanazawa Medical
University and at St. Luke Clinic from April 2006 to
March 2015. Because patients with relatively uncom-
mon LUF syndrome were enrolled in the study, the
study required a longer period of time; however,
the same evaluation methods were used throughout
the study. Written informed consent was obtained
from all study patients before the administration of
G-CSF. The study was conducted after being approved
by the Ethics Review Board of Kanazawa Medical Uni-
versity (Number 90).
Criteria for ovulation and LUF syndrome. We monitored
the patients’ follicular development by transvaginal
ultrasonography and with measurements of their serum
estradiol levels. Both ovulation and LUF syndrome
were diagnosed using serial transvaginal ultrasonogra-
phy in the period between the follicular and luteal phases
(Fig 1).Ovulationwas diagnosed if any of the following4
criteria were met after the hCG administration: (1)
reduction in the mean diameter of dominant follicles,
indicating the process of follicular rupture15; (2)
disappearance of the dominant follicles, indicating the
complete rupture of follicles; (3) morphologic changes
within the dominant follicles, indicating the
Fig 1. Diagnosis of LUF syndrome and the regimens of ovulation induction and G-CSF. Follicular development
was monitored by transvaginal ultrasonography and measurements of serum estradiol levels. LUF syndrome was
diagnosed using serial transvaginal ultrasonography in the period between the follicular and luteal phases. The
administration of hCG was started when follicular maturation was expected to occur because the mean follicular
diameter exceeded 18 mm with the serum estradiol level of.200 pg/mL. hCG was administered intramuscularly
(IM) at a dose of 5000 U. G-CSF (100 mg) was administered subcutaneously (SC) within 24–48 hours before the
administration of hCG. Clomiphene was administered orally once daily at a dose of 50 mg over a 5-day period
starting on Day 5 of the menstrual cycle. FSH was administered SC or IM at a dose of 75 U from around Day
5 of the menstrual cycle. FSH, follicle-stimulating hormone; G-CSF, granulocyte colony-stimulating factor;
hCG, human chorionic gonadotropin; LUF, luteinized unruptured follicle.
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follicular rupture into the postovulation follicles16; and
(4) in addition to criteria (1–3), marked echo-free space
in the Douglas pouch, indicating the accumulation of
follicular fluid or blood in the Douglas pouch after
ovulation.15 In some patients who had more than 1
developing follicle, ovulation was diagnosed if at least
1 follicle met any of the aforementioned criteria (1–4).
LUF syndrome was diagnosed if there was no
diagnostic evidence of ovulation.
Regimens. The dosing regimens for each constituent
drug were as follows (Fig 1): (1) clomiphene was
administered orally once daily initially at a dose of
50 mg (1 tablet) over a 5-day period starting on Day 5
of the menstrual cycle; (2) FSH was administered
subcutaneously or intramuscularly initially at a dose
of 75 U from around Day 5 of the menstrual cycle; (3)
hCG was administered intramuscularly at a dose of
5000 U in both the clomiphene 1 hCG therapy and
the FSH 1 hCG therapy groups. The administration
of hCG was started when follicular maturation was
expected to occur because the mean folliculardiameter exceeded 18 mm with a serum estradiol level
of .200 pg/mL; and (4) G-CSF (Neutrogin,
lenograstim; Chugai Pharmaceutical Co, Tokyo) was
administered subcutaneously at a dose of 100 mg
within 24–48 hours before the administration of hCG.
The timing of the G-CSF administration was defined
based on the following observations: (1) an increase in
the serum G-CSF level from Day 9 to 13 of the
menstrual cycle during ovulation induction,17 and, in
particular, (2) an increase in the serum G-CSF level
within 40 hours before the administration of hCG.18
Hematology. We measured the serum estradiol level
(picograms per milliliter) and the serum progesterone
level (nanograms per milliliter) on the day of the hCG
trigger and during the midluteal phase. The WBC count
(per microliter) and the serum G-CSF level (picograms
per milliliter) were determined on Day 0 (the day of the
G-CSF administration was defined as Day 0), 1, and 6
and thereafter. We used enzyme-linked immunoso-
rbent assays in the measurements of the serum G-CSF
levels (assay kit for human G-CSF, cat. no. 27131;
Immuno-Biological Laboratories, Fujioka, Japan).
Table I. Baseline characteristics of the 112 patients
with luteinized unruptured follicle syndrome
Overall
Clomiphene 1
hCG therapy
group
FSH 1 hCG
therapy
group
n 112 80 32
Age (mean 6 SD) 33.3 6 3.6 33.0 6 3.5 34.0 6 3.7
Height (cm) 158.4 6 5.0 158.2 6 5.2 159.0 6 4.5
Weight (kg) 52.9 6 7.1 53.2 6 7.1 52.2 6 7.1
BMI (kg/m2) 21.1 6 2.6 21.2 6 2.5 20.6 6 2.6
Number of pregnancies (n)
0 77 (68.8%) 55 (68.8%) 22 (68.8%)
1 17 (15.2%) 13 (16.3%) 4 (12.5%)
2 13 (11.6%) 9 (11.3%) 4 (12.5%)
3 5 (4.5%) 3 (3.8%) 2 (6.3%)
Number of deliveries (n)
0 90 (80.4%) 63 (78.8%) 27 (84.4%)
1 22 (19.6%) 17 (21.3%) 5 (15.6%)
Laparoscopic findings (n)
Endometriosis 62 (55.4%) 49 (61.3%) 13 (40.6%)
Fallopian tube
anomaly
19 (17.0%) 13 (16.3%) 6 (18.8%)
Pelvic adhesion 8 (7.1%) 4 (5.0%) 4 (12.5%)
PCO 3 (2.7%) 2 (2.5%) 1 (3.1%)
Uterine myoma 2 (1.8%) 1 (1.3%) 1 (3.1%)
Adenomyosis uteri 1 (0.9%) 1 (1.3%) 0 (0%)
No abnormalities 2 (1.8%) 2 (2.5%) 0 (0%)
Not tested 15 (13.4%) 8 (10.0%) 7 (21.9%)
rAFS score 10.5 6 18.9 11.9 6 20.5 6.5 6 12.6
Adhesion score 4.4 6 8.6 4.4 6 8.9 4.3 6 7.9
Abbreviations: BMI, body mass index; FSH, follicle-stimulating hor-
mone;G-CSF, granulocyte colony-stimulating factor; hCG, human
chorionic gonadotropin; PCO, polycystic ovary; rAFS, revised
American Fertility Society; SD, standard deviation.
Not tested: laparoscopy was not tested.
Percentages may not add up to 100% because of rounding.
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mean 6 standard deviation. The paired t tests, McNe-
mar test, and Dunnett test (2 sided) as multiple compar-
isons were performed to compare paired data from the
same individual patients. P values,0.05 were accepted
as representing significant differences. IBM Statistical
Package for the Social Sciences (SPSS) Statistics
version 21 (IBM, Armonk, NY) was used for all statis-
tical analyses.
RESULTS
Characteristics of patients. The overall (the
clomiphene 1 hCG therapy group and the
FSH 1 hCG therapy group) age of the total of 112
women with LUF syndrome was 33.3 6 3.6 years.
The overall body mass index was 21.1 6 2.6 kg/m2.
The gravidity numbers were as follows: nulligravida,
77 of 112 patients (68.8%); once, 17 of 112 patients
(15.2%); twice, 13 of 112 patients (11.6%); and thrice,
5 of 112 patients (4.5%). The parity numbers were as
follows: nulliparity, 90 of 112 patients (80.4%) and
once, 22 of 112 patients (19.6%). Of the 112 women,
62 (55.4%) were diagnosed with endometriosis by
laparoscopy. The overall revised American Fertility
Society score19 was 10.5 6 18.9. The overall adhesion
score was 4.4 6 8.6. Other overall results and data of
the women who received the clomiphene 1 hCG
therapy (n 5 80) or the FSH 1 hCG therapy (n 5 32)
are summarized in Table I.
Effects of G-CSF to prevent LUF syndrome during
ovulation induction. G-CSF was administered systemi-
cally by subcutaneous injection to 112 women with
LUF syndrome in combination with an ovulation
inducer (clomiphene, FSH, and hCG). Before our
analysis of the effects of G-CSF, 44 women were
excluded from the initial population for the following
reasons: (1) 13 became pregnant during the G-CSF
treatment cycle; (2) 11 switched their therapy to assis-
ted reproductive technology during the G-CSF
nontreatment control cycle; (3) 10 changed the
method of ovulation induction during the G-CSF
nontreatment control cycle; and (4) 10 were lost to
follow-up. Of the remaining 68 women analyzed, 46
were from the clomiphene 1 hCG therapy group
and the other 22 were from the FSH 1 hCG
therapy group (Fig 2).
In the overall group, the incidence of LUF syn-
drome in the G-CSF treatment cycle (4.4% [3/68
cycles]) was significantly reduced compared with
that in the G-CSF nontreatment control cycle
(19.1% [13/68 cycles]; P 5 0.013, McNemar test).
From the analysis of 46 women in the
clomiphene 1 hCG therapy group, we observed
that the incidence of LUF syndrome was decreasedby the additional use of G-CSF from 19.6% (9/46
cycles, the G-CSF nontreatment control cycle) to
4.3% (2/46 cycles, the G-CSF treatment cycle;
P 5 0.039, McNemar test). In the 22 women of the
FSH 1 hCG therapy group, there were no significant
differences in the incidence of LUF syndrome be-
tween the G-CSF treatment cycle (4.5%, 1/22 cycles)
and the G-CSF nontreatment control cycle (18.2%, 4/
22 cycles; P 5 0.375, McNemar test; Fig 3).
In the overall group and the clomiphene 1 hCG
therapy group, the following were not significantly
different from those of the G-CSF nontreatment con-
trol cycle: (1) the day of the hCG trigger; (2) the estra-
diol level on the day of the hCG trigger; (3) the
number of preovulatory follicles on the day of the
hCG trigger; (4) the estradiol level per preovulatory
follicle on the day of the hCG trigger; (5) the estradiol
level during the midluteal phase; and (6) the progester-
one level during the midluteal phase of the G-CSF
treatment cycle. In the FSH 1 hCG therapy group,
although the day of the hCG trigger of the G-CSF
Fig 2. Overall study flow. ART, assisted reproductive technology; FSH, follicle-stimulating hormone; G-CSF,
granulocyte colony-stimulating factor; hCG, human chorionic gonadotropin; LUF, luteinized unruptured follicle.
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G-CSF nontreatment control cycle, no significant dif-
ferences in other factors were observed between the
G-CSF treatment cycle and the G-CSF nontreatment
control cycle (Table II).
Pregnant women. In the present study, 13 women
established a clinical pregnancy during the G-CSF treat-
ment cycle. Among the pregnant women, the treatment
of 4 women was combined with embryo transfers (ETs).
The clinical pregnancy rate without ET when G-CSF
was used with the clomiphene 1 hCG therapy was
7.5% (6/80 women), and when G-CSF was used with
the FSH 1 hCG therapy, it was 9.4% (3/32 women).
The live birthrate without ET when G-CSF was used
with the clomiphene 1 hCG therapy was 6.3% (5/80
women), and when G-CSF was used with the
FSH 1 hCG therapy, it was 6.3% (2/32 women). The
mean age of the pregnant women was 33.86 3.3 years,
and the laparoscopic findings of the pregnant women
were as follows: (1) endometriosis (5/13 women,
38.5%); (2) fallopian tube anomaly (2/13 women,
15.4%); (3) pelvic adhesions (1/13 women, 7.7%);
and (4) no history of laparoscopy (5/13 women,
38.5%). The mean revised American Fertility Society
score was 11.3 6 17.7, and the mean adhesion score
was 2.8 6 4.7. The gravidity numbers were as follows:
nulligravida, 6 of 13 (46.2%); once, 4 of 13 (30.8%);
and twice, 3 of 13 (23.1%). The parity numbers were
as follows: nulliparity, 8 of 13 (61.5%) and once, 5 of
13 (38.5%).Hematology and safety. The WBC count transiently
increased to 19,622 6 4991/mL on Day 1 after the start
of the administration of G-CSF, but on Day 6 and
thereafter, the WBC count returned to 6738 6 1809/
mL, which was comparable to the baseline WBC count,
63546 1814/mL, observed on Day 0. The serum G-CSF
level on Day 1 (69.6 6 35.0 pg/mL) transiently
increased compared with Day 0 (10.8 6 4.2 pg/mL;
Table III). In the present study, no serious adverse
events because of the administration of G-CSF were
observed.
DISCUSSION
The results from the present study of 68 patients
showed the usefulness of G-CSF in preventing the onset
of LUF syndrome when administered in combination
with an ovulation inducer, especially in the
clomiphene 1 hCG therapy group. The frequency of
LUF syndrome was 25.1% in the patients who received
clomiphene15 and 20% in the patients who received a
clomiphene 1 gonadotropin regimen.20 The incidence
rates of LUF syndrome in the G-CSF nontreatment con-
trol cycle in the present study (the clomiphene 1 hCG
therapy, 19.6% and overall, 19.1%) were similar to
those of the previous reports. Qublan et al15 reported
that the rate of recurrence of LUF syndrome was as
high as 78.6% in patients receiving clomiphene. In the
present study, the incidence rates of LUF syndrome in
the G-CSF treatment cycle (the clomiphene 1 hCG
therapy with G-CSF, 4.3%; the FSH 1 hCG therapy
Fig 3. The ability of G-CSF to prevent LUF syndrome during
ovulation induction. G-CSF significantly inhibited LUF syndrome
induced by an overall ovulation inducer (the incidence of LUF syn-
drome: the G-CSF treatment cycle 4.4% [3/68 cycles], the G-CSF
nontreatment control cycle 19.1% [13/68 cycles], P 5 0.013). The
incidence of LUF syndrome induced by the clomiphene 1 hCG
therapy was significantly reduced by G-CSF (the G-CSF treatment
cycle 4.3% [2/46 cycles], the G-CSF nontreatment control cycle
19.6% [9/46 cycles], P 5 0.039). The additional use of G-CSF
was found to reduce the rate of onset of LUF syndrome to 4.5%
(1/22 cycles) during the FSH 1 hCG therapy. If G-CSF was not
administered, however, the corresponding rate of the onset
increased to 18.2% (4/22 cycles) (P 5 0.375). All statistical
analyses were performed using the McNemar test. FSH, follicle-
stimulating hormone; G-CSF, granulocyte colony-stimulating
factor; hCG, human chorionic gonadotropin; LUF, luteinized un-
ruptured follicle.
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that G-CSF had marked an ovulation-promoting
activity.
The G-CSF level in serum transiently increased on
Day 1 (69.6 6 35.0 pg/mL), which was higher than
that of the periovulatory phase in the physiological
menstrual cycle (11.2 6 1.2 pg/mL) that we re-
ported.21 The half-life of G-CSF after subcutaneous
administration was estimated to be 6–12 hours,22 sug-
gesting only short-term efficacy of G-CSF in vivo. On
the other hand, the half-life of neutrophils is as long
as 3.75 days,23 which can be further prolonged in thepresence of G-CSF at the site of inflammation.24
Because the present study involved the administration
of hCG within 24–48 hours after the administration
of G-CSF and assuming that ovulation occurred
approximately 36 hours after the administration of
hCG, we estimated that ovulation would occur during
the period between 2.5 days (5[24 1 36 h]/24 h) and
3.5 days (5[48 1 36 h]/24 h) after the G-CSF
administration. Considering the setting of the duration
of the period from the G-CSF administration until
ovulation in the present study, we suspect that the
neutrophils with a longer half-life, rather than
G-CSF with a shorter half-life, had an effect on
ovulation.
The administration of leukocytes was found to mark-
edly increase the number of ovulations in an ovarian-
perfusion rat model,25 whereas the administration of
neutrophil-depleting antibodies (RP-3) reduced the
ovulation rate in the same rat model.26 These reports
demonstrated that neutrophils play an important role
in ovulation, particularly in the rupturing of the follicle.
As the probable reason for the promotion of ovulation
by G-CSF administration observed in the present study,
we suggest that G-CSF may contribute to ovulation by
increasing the systemic neutrophil counts, thereby
increasing neutrophil counts in the thecal layer in a pro-
portional manner.
The impact of G-CSF on pregnancy remain contro-
versial. The clinical pregnancy rate of the
clomiphene 1 hCG therapy with G-CSF in the present
study (7.5%) showed little difference from that of the
clomiphene 1 hCG therapy without G-CSF (8.9%),
which was previously reported by Macgregor et al.27
Scarpellini and Sbracia28 demonstrated that the subcu-
taneous administration of G-CSF increased the birthrate
among women suffering from habitual abortion.
Gleicher et al29,30 reported that the direct adminis-
tration of G-CSF to the endometrium improved the
thickness of the endometrium (,7 mm) that was
unsuitable for implantation. Nonetheless, Barad et al31
reported that intrauterine perfusions with G-CSF did
not affect the clinical pregnancy rates in in vitro fertil-
ization patients.
This study revealed the usefulness of G-CSF with
neutrophil-stimulating activity as a novel therapy for
LUF syndrome in clinical practice. Our findings can
be expected to have an impact on current infertility
treatments. This low-cost and easy-to-use G-CSF tech-
nique could be widely used in the future for the treat-
ment of anovulatory women with repeated episodes of
LUF syndrome, instead of the immediate prescription
of assisted reproductive technology without careful
consideration.
Table II. Characteristics of the G-CSF treatment cycle and the G-CSF nontreatment control cycle
G-CSF treatment cycle G-CSF nontreatment control cycle P values
Overall (cycles [n] 5 68)
Day of hCG trigger
Day of the menstrual cycle (d) 14.9 6 3.0 15.5 6 3.5 0.104
Estradiol (pg/mL) 568.4 6 446.6 514.0 6 322.9 0.290
Number of preovulatory follicles (n) 1.8 6 1.1 1.7 6 1.0 0.634
Estradiol per preovulatory follicle (pg/mL) 358.0 6 173.4 433.2 6 215.6 0.318
Midluteal phase
Day of the menstrual cycle (d) 23.0 6 3.5 23.4 6 3.7 0.462
Estradiol (pg/mL) 427.7 6 419.3 401.4 6 366.5 0.650
Progesterone (ng/mL) 24.1 6 19.4 25.4 6 17.3 0.590
Clomiphene 1 hCG therapy group (cycles [n] 5 46)
Day of hCG trigger
Day of the menstrual cycle (d) 14.6 6 2.7 14.7 6 2.3 0.831
Estradiol (pg/mL) 605.1 6 521.2 554.1 6 355.0 0.472
Number of preovulatory follicles (n) 2.2 6 1.3 2.0 6 1.2 0.622
Estradiol per preovulatory follicle (pg/mL) 344.1 6 194.0 486.1 6 258.7 0.263
Midluteal phase
Day of the menstrual cycle (d) 23.0 6 3.2 22.9 6 2.6 0.800
Estradiol (pg/mL) 424.6 6 345.0 470.9 6 413.4 0.414
Progesterone (ng/mL) 29.0 6 21.9 30.4 6 18.4 0.666
FSH 1 hCG therapy group (cycles [n] 5 22)
Day of hCG trigger
Day of the menstrual cycle (d) 15.5 6 3.5 17.1 6 5.0 0.027
Estradiol (pg/mL) 491.4 6 211.9 429.9 6 227.8 0.312
Number of preovulatory follicles (n) 1.2 6 0.4 1.2 6 0.4 1.000
Estradiol per preovulatory follicle (pg/mL) 377.6 6 159.5 359.0 6 125.1 0.727
Midluteal phase
Day of the menstrual cycle (d) 23.0 6 4.1 24.3 6 5.1 0.160
Estradiol (pg/mL) 433.5 6 543.1 268.7 6 202.8 0.205
Progesterone (ng/mL) 14.9 6 7.7 15.9 6 9.5 0.728
Abbreviations: FSH, follicle-stimulating hormone; G-CSF, granulocyte colony-stimulating factor; hCG, human chorionic gonadotropin.
Values are the mean 6 standard deviation. Paired t test was used for the statistical analyses.
Table III. Hematologic findings in the patients after the administration of G-CSF
Day*
WBC (/mL) G-CSF (pg/mL)
Count P value vs Day 0 Serum level P value vs Day 0
0 6354 6 1814 n.d. 10.8 6 4.2 n.d.
1 19,622 6 4991 ,0.001 69.6 6 35.0 ,0.001
6 and thereafter 6738 6 1809 0.611 20.9 6 13.9 0.031
Abbreviations: G-CSF, granulocyte colony-stimulating factor; n.d., not done; WBC, white blood cell.
Values are the mean 6 standard deviation. The Dunnett test was used for the statistical analyses.
*Day 0 was defined as the day of G-CSF administration (control).
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